Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | HTR2B | P41595 | 3/20 | 0.47 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.40 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.40 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.40 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.40 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.40 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.40 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.40 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.40 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16518063 | 0.88 | ERN1 (0.41) | HTR2CHTR2AHTR2BHTR1ACYP1A2 | |
| Bromide SCHEMBL38652851 | 0.86 | ERN1 (0.40) | HTR2CHTR2AHTR2BHTR1ACYP1A2 | |
| SCHEMBL23674930 | 0.84 | CYP1A2 (0.45) | HTR1ACYP1A2CYP2D6DRD2PKM | |
| SCHEMBL8432407 | 0.80 | CYP1A2 (0.42) | HTR2AHTR1ACYP1A2CYP2D6DRD2 | |
| SCHEMBL12118828 | 0.80 | BCL2L1 (0.45) | HTR1ACYP1A2CYP2D6DRD2PKM | |
| SCHEMBL2258843 | 0.76 | HTR2C (0.47) | HTR2CHTR2AHTR2BHTR7HTR3A | |
| SCHEMBL8909616 | 0.75 | HTR2C (0.50) | HTR2CHTR2AHTR2BADCY6ADCY3 | |
| Hydrochloric Acid SCHEMBL1198541 | 0.74 | HTR2C (0.46) | HTR2CHTR2AHTR2BHTR7HTR3A | |
| Hydrochloric Acid SCHEMBL21521392 | 0.72 | LMNA (0.36) | HTR2CHTR1ACYP1A2CYP2D6DRD2 | |
| SCHEMBL10349225 | 0.72 | DRD2 (0.45) | HTR1ACYP1A2CYP2D6DRD2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794563-B1 | HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-9255090-B2 | Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-09 | — | — | US | disclosed |
| US-20150252036-A1 | Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| EP-2794563-A1 | HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093842-A1 | HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252036-A1 | Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators | PTGDR, PTGER1, PTGDR2 | HTR2C 288/4885HTR2A 265/4885HTR2B 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.